Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study
Open Access
- 27 August 2002
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 87 (5), 497-501
- https://doi.org/10.1038/sj.bjc.6600482
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II studyBritish Journal of Cancer, 2000
- Current chemotherapeutic possibilities in pancreaticobiliary cancerAnnals of Oncology, 1999
- Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinomaBritish Journal of Cancer, 1999
- Treatment of Pancreatic Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor: A Multicenter Phase II StudyJournal of Clinical Oncology, 1999
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerAnnals of Oncology, 1996
- Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreasInvestigational New Drugs, 1994
- Cancer in the European community and its member statesEuropean Journal of Cancer and Clinical Oncology, 1990
- Reporting results of cancer treatmentCancer, 1981
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961